Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea flag South Korea · Delayed Price · Currency is KRW
417,000
+9,500 (2.33%)
Last updated: Aug 11, 2026, 10:58 AM KST

Hanmi Pharm. Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,549,5091,547,5311,495,5021,490,8871,331,5471,203,186
Other Revenue
0-0---0-
1,549,5091,547,5311,495,5021,490,8871,331,5471,203,186
Revenue Growth
4.50%3.48%0.31%11.97%10.67%11.83%
Cost of Revenue
661,405663,124678,465661,638612,994570,433
Gross Profit
888,104884,407817,037829,249718,553632,752
Selling, General & Admin
428,195430,773421,960426,789406,146361,309
Research & Development
207,481195,834178,891181,769154,317146,027
Operating Expenses
677,515660,536604,526604,364564,657507,336
Operating Income
210,588223,870212,511224,885153,896125,416
Interest Expense
-15,292-16,986-24,374-28,508-22,647-16,577
Interest & Investment Income
8,2797,2665,6664,6187,8565,722
Earnings From Equity Investments
-18.91-7.45-9.21,258-8,537-4.02
Currency Exchange Gain (Loss)
9,9171,4349,3181,039-2,64113.07
Other Non Operating Income (Expenses)
951.15-3,949-29,309-4,571-3,620-9,277
EBT Excluding Unusual Items
214,424211,628173,802198,721124,308105,293
Gain (Loss) on Sale of Investments
4,3294,762-87.922,63047.09-
Gain (Loss) on Sale of Assets
16.26101.227.741,769451.65-1,062
Asset Writedown
-3,088-3,013-2,488-9,153-3,794-535.2
Pretax Income
215,681213,478171,254193,967121,013103,697
Income Tax Expense
22,11626,34230,82328,60119,45422,218
Earnings From Continuing Operations
193,565187,136140,431165,366101,55881,478
Minority Interest in Earnings
-21,126-17,581-19,116-19,135-18,766-14,453
Net Income
172,439169,554121,315146,23182,79267,025
Net Income to Common
172,439169,554121,315146,23182,79267,025
Net Income Growth
58.32%39.76%-17.04%76.63%23.52%460.45%
Shares Outstanding (Basic)
131313131313
Shares Outstanding (Diluted)
131313131313
Shares Change
0.08%0.07%-0.08%-0.09%-0.12%-0.11%
EPS (Basic)
13597.3513371.579566.8311522.126517.335269.87
EPS (Diluted)
13587.9413362.009566.8311522.126517.335269.87
EPS Growth
58.19%39.67%-16.97%76.79%23.67%461.07%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
153,918130,048154,226189,186131,890181,974
Free Cash Flow Per Share
12128.3710248.7712162.1314906.6710382.3714307.73
Dividend Per Share
2000.0002000.000----
Dividend Growth
------
Gross Margin
57.32%57.15%54.63%55.62%53.96%52.59%
Operating Margin
13.59%14.47%14.21%15.08%11.56%10.42%
Profit Margin
11.13%10.96%8.11%9.81%6.22%5.57%
Free Cash Flow Margin
9.93%8.40%10.31%12.69%9.90%15.12%
EBITDA
309,618322,679309,842323,339250,738214,502
EBITDA Margin
19.98%20.85%20.72%21.69%18.83%17.83%
D&A For EBITDA
99,02998,80997,33198,45496,84289,086
EBIT
210,588223,870212,511224,885153,896125,416
EBIT Margin
13.59%14.47%14.21%15.08%11.56%10.42%
Effective Tax Rate
10.25%12.34%18.00%14.74%16.08%21.43%
Advertising Expenses
-73,81778,78976,03472,62762,201